Cite

    Rowan, C. et al. (2018). Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study. Alimentary pharmacology & therapeutics. 48 (3), pp. 333-339. [Online].